Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (5,876)	$ (3,370)	$ (9,455)	$ (7,160)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment			325	340
Redeemable warrants valuation adjustment			29	150
Warrant modification				46
Extinguishment of financing obligation and note payable			2,701	142
Amortization of patent, trademark rights			80	67	$ 158
Changes in ROU assets			22	22
Gain on sale of property and equipment			(216)
Gain from sale of income tax operating losses	(288)		(469)
Equity-based compensation			1,006	346
Realized (loss) gain on sale of marketable securities			25	63
Amortization of finance and debt issuance costs			47	42
Change in assets and liabilities:
Accounts receivable			6	4
Funds Receivable from New Jersey net operating loss			1,090	770
Prepaid expenses and other current assets and other non-current assets			69	730
Lease liability			(22)	(22)
Accounts payable			68	(217)
Accrued interest expense				230
Accrued expenses			(69)	(78)
Net cash used in operating activities			(4,763)	(4,525)
Cash flows from investing activities:
Proceeds from sale of marketable securities			1,613	8,497
Purchase of marketable securities			(2,096)	(7,590)
Purchase of property and equipment			(26)	(9)
Proceeds from sale of property and equipment			245
Purchase of patent and trademark rights			(365)	(297)
Net cash (used in) provided by investing activities			(629)	601
Cash flows from financing activities:
Payment and note payable				(4,283)
Payment of financing obligation			(4,732)
Financing obligation payments			(122)	(176)
Proceeds from sale of stock, net of issuance costs			12,887	40,821
Net cash provided by financing activities			8,033	36,362
Net increase in cash and cash equivalents			2,641	32,438
Cash and cash equivalents at beginning of period			38,501	1,470	1,470
Cash and cash equivalents at end of period	$ 41,142	$ 33,908	41,142	33,908	$ 38,501
Supplemental disclosures of non-cash investing and financing cash flow information:
Stock issued to settle accounts payable				10
Unrealized loss on marketable securities			(225)	63
Conversion of Series B preferred			$ 7	$ 41